Biotech News

Synlogic Reports First Quarter 2024 Financial Results

Synlogic (SYBX)SynlogicEarnings

CAMBRIDGE, Mass. , May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.

Open original release

Related news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

Stock data

Close
0.67 USD
Market cap
Exchange
NASDAQ
Sector
Biopharma
Location
United States